CytoSorbents Corporation (CTSO)

[CLCary]

Shelf sales so far this year:

Taken from the 12-31-17 10-K; pg 39

"From January 1, 2018 through March 7, 2018 we sold an additional 465,112
shares of our common stock at an average price of $7.91 per share, generating net proceeds of approximately $3.57 million"

I like this. Well done. Sold right at the top of the chart's resistance and executed. My guess it was mostly since 2/21.

Hope Chan is right in that the cash flow from operations reaches all needs, less non-cash expenses and trial needs sometime this year (viewed from a quarterly perspective.) If so, we will be trading above 8.20 thereon and future needs of capital will be much less proportionally dilutive.

Now, if the general market doesn't take too bad a dump this year and next.